Study wrapper · #698
Correction of Lipid Metabolism Disorders in Diabetes Mellitus with Peptide Drugs.
Editor's note
In a streptozotocin-induced rat model of diabetes, researchers reported that both deltalicin and Semax (200 microg/kg) improved several lipid measures, lowering total cholesterol, triglycerides, LDL and atherogenic index while raising HDL, comparably to the reference drug sulodexide, with deltalicin appearing more potent than either. For Semax specifically, this is a secondary finding in a study centered on deltalicin, and Semax was the weaker of the two peptides. It adds a metabolic angle to Semax's mostly neuro-focused literature, but it is small, preclinical, and not the paper's main subject. Low weight. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
Diabetes often disturbs blood fats (lipids), raising heart-disease risk. This rat study, done in animals given a drug to induce diabetes, tested whether two peptides, deltalicin and Semax, could improve their lipid profiles. Both peptides, like a standard comparison drug, lowered total cholesterol, triglycerides and 'bad' LDL cholesterol, reduced a marker of artery risk, and raised 'good' HDL cholesterol. Deltalicin had the strongest effect, more than Semax or the comparison drug. Because the study focused mainly on deltalicin and Semax was the weaker performer, it offers only a secondary hint about Semax and blood fats. This is laboratory work in diabetic rats and does not show a benefit in people.